1041423-26-0

Basic information

• Product Name: 1,3-Dichloro-6-fluoroisoquinoline
• Synonyms: 1,3-Dichloro-6-fluoroisoquinoline;1,3-Dichloro-6-fluoroisoquinoline 97%
• CAS NO: 1041423-26-0
• Molecular Formula: C9H4Cl2FN
• Molecular Weight: 216.0391632
• Product Categories: Heterocyclic Building BlocksHeterocyclic Building Blocks;Chemical Synthesis;Halogenated Heterocycles;Isoquinolines;New Products for Chemical Synthesis
• Mol File: 1041423-26-0.mol

Chemical Properties

• Melting Point: 131-133 °C
• Boiling Point: 332.3 °C at 760 mmHg
• Flash Point: 154.7 °C
• Appearance: /
• Density: 1.491 g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 1,3-Dichloro-6-fluoroisoquinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-Dichloro-6-fluoroisoquinoline(1041423-26-0)
• EPA Substance Registry System: 1,3-Dichloro-6-fluoroisoquinoline(1041423-26-0)

Safety Data

• Hazard Codes: Xn
• Statements: 22-37/38-41
• Safety Statements: 26-36/37
• RIDADR: UN 2811 6.1/PG 3
• WGK Germany: 3
• Hazardous Substances Data: 1041423-26-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1,3-Dichloro-6-fluoroisoquinoline is used as a key intermediate in the synthesis of various pharmaceuticals and agrochemicals. Its unique structure and functional groups make it a valuable building block for the development of new drugs and agrochemicals with improved properties and therapeutic effects.
Used in Medicinal Chemistry:
1,3-Dichloro-6-fluoroisoquinoline is used as a lead compound in medicinal chemistry for the discovery and optimization of new therapeutic agents. Its potential medicinal and biological properties have been studied, particularly in the treatment of infections and cancer. Researchers are exploring its ability to target specific biological pathways and modulate cellular processes, leading to the development of novel therapeutic agents.
Used in Drug Synthesis:
1,3-Dichloro-6-fluoroisoquinoline is used as a starting material or a building block in the synthesis of various drug candidates. Its chemical reactivity and structural diversity allow for the generation of a wide range of drug-like molecules with potential therapeutic applications. 1,3-Dichloro-6-fluoroisoquinoline can be further modified and functionalized to enhance its pharmacological properties and improve its drug-like characteristics.
Used in Agrochemical Development:
1,3-Dichloro-6-fluoroisoquinoline is also used in the development of agrochemicals, such as pesticides and herbicides. Its unique chemical structure and properties make it a promising candidate for the design of new agrochemicals with improved efficacy, selectivity, and environmental compatibility.
However, it is important to note that 1,3-Dichloro-6-fluoroisoquinoline should be handled with caution due to its potential hazards to human health and the environment. Proper safety measures and guidelines should be followed during its synthesis, handling, and application to minimize any adverse effects.

Upstream product

• 162751-93-1 (E)-5-fluoro-2-(hydroxyimino)-2,3-dihydroinden-1-one 
• 700-84-5 5-fluoro-1-indanone 

Downstream Products

• 1041423-28-2 3-chloro-6-fluoroisoquinoline 
• 1446192-30-8 3-chloro-6-fluoro-1-methylisoquinoline 

Relevant articles and documents

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme glycolate oxidase (GO). Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

Discovery of 6-(Fluoro-18F)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine ([18F]-MK-6240): A Positron Emission Tomography (PET) Imaging Agent for Quantification of Neurofibrillary Tangles (NFTs)

Neurofibrillary tangles (NFTs) made up of aggregated tau protein have been identified as the pathologic hallmark of several neurodegenerative diseases including Alzheimer's disease. In vivo detection of NFTs using PET imaging represents a unique opportuni

PYRROLO[2,3-C]PYRIDINES AS IMAGING AGENTS FOR NEUROFIBRILARY TANGLES

Pyrrolopyridine compounds of formula (I) or their pharmaceutically acceptable salts are disclosed, which may be suitable for imaging tau aggregates, b-sheet aggregates, beta-amyloid aggregates or alpha- synuclein aggregates, and hence are useful in binding and imaging tau aggregates in Alzheimer's patients. More specifically, the compounds are used as tracers in positron emission tomography (PET) imaging to study tau deposits in brain in vivo to allow diagnosis of Alzheimer's disease and other neurodegenerative diseases characterized by tau pathology. Futher, the compounds are useful for measuring clinical efficacy of therapeutic agents for Alzheimer's disease and other neurodegenerative diseases characterized by tau pathology.

CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLINE DERIVATIVES

The invention relates to 6-substituted isoquinoline derivatives of the Formula (I) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.

ISOQUINOLINE DERIVATIVES AS INHIBITORS OF RHO-KINASE

The invention relates to 6-piperidinyl-substituted isoquinoline derivatives of the formula (I); useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.